MEI Pharma Rides Wave Of Interest in AML
MEI Pharma CEO Dan Gold explains Phase III plans for the oral HDAC inhibitor pracinostat in acute myeloid leukemia and why there is still room in the market for a new PI3 kinase inhibitor like MEI-401 in B-cell malignancies in an interview at the Biotech Showcase.
You may also be interested in...
Public Company Edition: Kiniksa, Scholar Rock and Iterum launch the most recent US IPOs and at least five more drug developers join the queue. Also, Polyphor go public in Switzerland, Valeant and Ligand sell notes, and MyoKardia led recent follow-on offerings.
Unmet need in acute myeloid leukemia is very high, but that doesn't mean standards will be low for the many companies pursuing therapies in the space.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.